Table 3. Association of 5-year absolute survival rate with sociodemographic and clinical characteristics of patients (N=152).
| Survived | Bivariable, unadjusted analysis | Multivariable, adjusted analysis | ||||||
|---|---|---|---|---|---|---|---|---|
| n | (%) | OR | (95% CI) | p | OR | (95% CI) | p | |
| Age (years) | n.a. | 0.96 | (0.94-0.99) | 0.005 | 0.95 | (0.92-0.99) | 0.007 | |
| Menopause*: | ||||||||
| No | 43 | (79.6) | 1 | |||||
| Yes | 69 | (70.4) | 0.61 | (0.28-1.34) | 0.219 | |||
| Comorbidities†: | ||||||||
| No | 45 | (71.4) | 1 | 1 | ||||
| Yes | 67 | (75.3) | 1.22 | (0.59-2.52) | 0.595 | 1.68 | (0.60-4.73) | 0.323 |
| Histopathology: | ||||||||
| Other | 19 | (79.2) | 1 | 1 | ||||
| Ductal carcinoma (NOS) | 93 | (72.7) | 0.70 | (0.24-202) | 0.508 | 0.76 | (0.22-2.57) | 0.657 |
| Tumor size | n.a. | 0.69 | (0.54-0.88) | 0.003 | 0.65 | (0.48-0.88) | 0.006 | |
| Number of positive lymph nodes | n.a. | 0.75 | (0.65-0.85) | <0.001 | 0.78 | (0.67-0.90) | 0.001 | |
| Grade | ||||||||
| I-II | 20 | (71.4) | 1 | 1 | ||||
| III | 92 | (74.2) | 1.15 | (0.46-2.87) | 0.764 | 0.74 | (0.26-2.11) | 0.579 |
| Ki67 | n.a. | 1.01 | (1.00-1.02) | 0.154 | 1.02 | (1.00-1.04) | 0.083 | |
| Type of surgery: | ||||||||
| Conservative | 81 | (87.1) | 1 | |||||
| Radical | 31 | (52.5) | 0.16 | (0.07-0.36) | <0.001 | |||
| Adjuvant chemotherapy: | ||||||||
| None | 13 | (54.2) | 1 | |||||
| Other | 5 | (35.7) | 0.47 | (0.12-1.82) | 0.275 | |||
| Anthracyclines | 63 | (88.7) | 6.66 | (2.24-19.80) | 0.001 | |||
| Anthracyclines and taxanes | 31 | (72.1) | 2.19 | (0.77-6.21) | 0.142 | |||
n.a. = not available; n = number of patients; OR = odds ratio; CI = confidence interval; p = statistical significance calculated using binary logistic regression; NOS = not otherwise specified; *data were missing for 6 (3.9%) patients and were imputed using multiple imputation; †menopausal status was excluded from multivariable analysis to prevent multicollinearity with age.